You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDomperidone
Accession NumberDB01184  (APRD00418)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]
Structure
Thumb
Synonyms
1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
Domperidona
Domperidonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-domperidoneTablet10 mgOralAvanstra Inc2011-09-152014-08-21Canada
Bio-domperidoneTablet10 mgOralBiomed Pharma2016-04-26Not applicableCanada
Dom-domperidoneTablet10 mgOralDominion Pharmacal1998-09-17Not applicableCanada
DomperidoneTablet10 mgOralSanis Health Inc2010-05-12Not applicableCanada
DomperidoneTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
DomperidoneTablet10 mgOralSivem Pharmaceuticals Ulc1998-09-03Not applicableCanada
Domperidone-10Tablet10 mgOralPro Doc Limitee1998-07-13Not applicableCanada
Ftp-domperidone MaleateTablet10 mgOralGmd Distribution Inc.1998-10-092005-08-05Canada
Ipg-domperidoneTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-domperidoneTablet10 mgOralJamp Pharma Corporation2011-10-07Not applicableCanada
Mar-domperidoneTablet10 mgOralMarcan Pharmaceuticals Inc2014-01-02Not applicableCanada
MotilidoneTablet10 mgOralTechnilab Pharma Inc.1997-09-172005-08-05Canada
Motilium Tab 10mgTablet10 mgOralJanssen Inc1990-12-312002-01-07Canada
Mylan-domperidoneTablet10 mgOralMylan Pharmaceuticals Ulc2006-03-20Not applicableCanada
Nu-domperidone 10 Mg TabletsTablet10 mgOralNu Pharm Inc1998-03-182012-09-04Canada
PMS-domperidoneTablet10 mgOralPharmascience Inc1997-11-13Not applicableCanada
Priva-domperidoneTablet10 mgOralPharmapar IncNot applicableNot applicableCanada
Ran-domperidoneTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-05Not applicableCanada
Ratio-domperidoneTablet10 mgOralTeva Canada Limited1993-12-31Not applicableCanada
Teva-domperidoneTablet10 mgOralTeva Canada Limited1997-09-17Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-domperidone - Tab 10mgTablet10 mgOralApotex Inc1997-09-17Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EucitonRoux-Ocefa
MoperidonaSidus
MotiliumJanssen
NauzelinKyowa Hakko Kirin
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5587267Z69
CAS number57808-66-9
WeightAverage: 425.911
Monoisotopic: 425.161852744
Chemical FormulaC22H24ClN5O2
InChI KeyFGXWKSZFVQUSTL-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
IUPAC Name
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2
Pharmacology
IndicationFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
Structured Indications
PharmacodynamicsDomperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Mechanism of actionDomperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(3) dopamine receptorProteinyes
antagonist
HumanP35462 details
Related Articles
AbsorptionFast
Volume of distributionNot Available
Protein binding91%-93%
Metabolism
SubstrateEnzymesProduct
Domperidone
5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-oneDetails
Route of eliminationNot Available
Half life7 hours
ClearanceNot Available
ToxicitySide effects include galactorrhea, gynecomastia, or menstrual irregularities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Domperidone.Experimental
AbirateroneThe serum concentration of Domperidone can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Domperidone can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Domperidone can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Domperidone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Domperidone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Domperidone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Domperidone can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Domperidone.Approved
Aminohippuric acidThe serum concentration of Domperidone can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Domperidone.Approved
AmlodipineThe serum concentration of Domperidone can be increased when it is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Domperidone.Approved
AmprenavirThe serum concentration of Domperidone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Domperidone can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Domperidone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AprepitantThe serum concentration of Domperidone can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
ArtemetherDomperidone may increase the QTc-prolonging activities of Artemether.Approved
AsenapineDomperidone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Domperidone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Domperidone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Domperidone can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Domperidone can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Domperidone can be increased when it is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Domperidone.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Domperidone.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Domperidone.Withdrawn
BenzocaineThe serum concentration of Domperidone can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Domperidone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Domperidone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Domperidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Domperidone can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Domperidone can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Domperidone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Domperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Domperidone can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Domperidone can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Domperidone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Domperidone can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Domperidone.Approved
BuspironeThe serum concentration of Domperidone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Domperidone can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Domperidone can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Domperidone can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Domperidone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Domperidone can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Domperidone can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Domperidone.Withdrawn
CarvedilolThe serum concentration of Domperidone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Domperidone can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Domperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Domperidone can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Domperidone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Domperidone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Domperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Domperidone can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Domperidone can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Domperidone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Domperidone can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Domperidone can be decreased when combined with Cinacalcet.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Domperidone.Approved
ClarithromycinThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Domperidone can be increased when it is combined with Clemastine.Approved
ClobazamThe metabolism of Domperidone can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Domperidone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
ClopidogrelThe metabolism of Domperidone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Domperidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Domperidone.Approved
CobicistatThe serum concentration of Domperidone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Domperidone can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Domperidone can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Domperidone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Domperidone can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Domperidone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Domperidone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Domperidone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Domperidone can be increased when it is combined with Dactinomycin.Approved
DarifenacinThe metabolism of Domperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Domperidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Domperidone can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Domperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Domperidone.Approved
DelavirdineThe serum concentration of Domperidone can be increased when it is combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Domperidone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Domperidone.Approved
DesloratadineThe serum concentration of Domperidone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Domperidone can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Domperidone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Domperidone can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Domperidone can be increased when it is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Domperidone.Approved
DipyridamoleThe serum concentration of Domperidone can be increased when it is combined with Dipyridamole.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Domperidone.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Domperidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Domperidone.Approved
DoxazosinThe serum concentration of Domperidone can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Domperidone.Approved
DoxorubicinThe serum concentration of Domperidone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Domperidone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Domperidone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Domperidone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
DuloxetineThe metabolism of Domperidone can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Domperidone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Domperidone can be increased when it is combined with Elbasvir.Approved
EliglustatDomperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Domperidone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Domperidone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Domperidone can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
ErythromycinThe serum concentration of Domperidone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Domperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Domperidone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Domperidone can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Domperidone can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Domperidone can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Domperidone can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Domperidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Domperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Domperidone.Approved
FelodipineThe serum concentration of Domperidone can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Domperidone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Domperidone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Domperidone can be increased when it is combined with Fidaxomicin.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Domperidone.Approved, Withdrawn
FluconazoleThe serum concentration of Domperidone can be increased when it is combined with Fluconazole.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Domperidone.Approved, Withdrawn
FluphenazineThe serum concentration of Domperidone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Domperidone can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Domperidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
FosamprenavirThe serum concentration of Domperidone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Domperidone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Domperidone.Approved
FosphenytoinThe metabolism of Domperidone can be increased when combined with Fosphenytoin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Domperidone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Domperidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Domperidone.Approved
GefitinibThe serum concentration of Domperidone can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Domperidone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
GenisteinThe serum concentration of Domperidone can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Domperidone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Domperidone can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Domperidone.Approved
Gramicidin DThe serum concentration of Domperidone can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
GrepafloxacinThe serum concentration of Domperidone can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Domperidone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Domperidone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Domperidone.Approved
HydrocortisoneThe serum concentration of Domperidone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Domperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Domperidone.Approved
IdelalisibThe serum concentration of Domperidone can be increased when it is combined with Idelalisib.Approved
IloperidoneDomperidone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Domperidone can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Domperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Domperidone.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Domperidone.Approved
IndinavirThe serum concentration of Domperidone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Domperidone can be increased when it is combined with Indomethacin.Approved, Investigational
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Domperidone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.Withdrawn
IrbesartanThe metabolism of Domperidone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Domperidone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
IsoniazidThe metabolism of Domperidone can be decreased when combined with Isoniazid.Approved
IsradipineThe serum concentration of Domperidone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Domperidone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Domperidone.Approved
IvacaftorThe serum concentration of Domperidone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Domperidone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Domperidone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Domperidone can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Domperidone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Domperidone.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LevothyroxineThe serum concentration of Domperidone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Domperidone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Domperidone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Domperidone can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Domperidone can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Domperidone.Approved
LomitapideThe serum concentration of Domperidone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Domperidone can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Domperidone can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Domperidone can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Domperidone can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Domperidone can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Domperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Domperidone can be increased when it is combined with Lumacaftor.Approved
LumefantrineDomperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Domperidone.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Domperidone.Withdrawn
MebendazoleThe serum concentration of Domperidone can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Domperidone.Approved
Megestrol acetateThe serum concentration of Domperidone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Domperidone can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneMethadone may increase the QTc-prolonging activities of Domperidone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Domperidone.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Domperidone.Investigational
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
MetoprololThe serum concentration of Domperidone can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Domperidone.Approved
MexiletineThe metabolism of Domperidone can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Domperidone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Domperidone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Domperidone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Domperidone.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Domperidone.Approved
MitomycinThe serum concentration of Domperidone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Domperidone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Domperidone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.Approved
ModafinilThe serum concentration of Domperidone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Domperidone.Approved
MorphineThe serum concentration of Domperidone can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
NafcillinThe serum concentration of Domperidone can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Domperidone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Domperidone can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Domperidone can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Domperidone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Domperidone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Domperidone can be increased when it is combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Domperidone.Approved
NifedipineThe serum concentration of Domperidone can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Domperidone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Domperidone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Domperidone can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Domperidone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Domperidone.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Domperidone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Domperidone.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Domperidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
OlaparibThe serum concentration of Domperidone can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Domperidone.Approved
OmeprazoleThe serum concentration of Domperidone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Domperidone.Approved
OsimertinibThe serum concentration of Domperidone can be increased when it is combined with Osimertinib.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
P-NitrophenolThe serum concentration of Domperidone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Domperidone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneDomperidone may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Domperidone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Domperidone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Domperidone can be increased when it is combined with Pantoprazole.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Domperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Domperidone.Approved
Peginterferon alfa-2bThe serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Domperidone.Approved
PentobarbitalThe metabolism of Domperidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Domperidone.Approved
PerindoprilThe serum concentration of Domperidone can be increased when it is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Domperidone.Withdrawn
PhenobarbitalThe metabolism of Domperidone can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Domperidone.Withdrawn
PhenytoinThe metabolism of Domperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Domperidone.Approved
PioglitazoneThe metabolism of Domperidone can be decreased when combined with Pioglitazone.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Domperidone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Domperidone.Withdrawn
Platelet Activating FactorThe serum concentration of Domperidone can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Domperidone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Domperidone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Domperidone can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Domperidone can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Domperidone can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Domperidone.Approved
PrimidoneThe metabolism of Domperidone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Domperidone can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Domperidone.Approved
ProgesteroneThe serum concentration of Domperidone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Domperidone.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Domperidone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Domperidone can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Domperidone.Approved
QuazepamThe serum concentration of Domperidone can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Domperidone can be increased when it is combined with Quercetin.Experimental
QuetiapineDomperidone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Domperidone can be increased when it is combined with Quinacrine.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Domperidone.Approved
QuinineQuinine may increase the QTc-prolonging activities of Domperidone.Approved
RabeprazoleThe metabolism of Domperidone can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Domperidone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Domperidone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.Approved
ReboxetineThe serum concentration of Domperidone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Domperidone can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Domperidone can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Domperidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Domperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Domperidone can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Domperidone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
RitonavirThe serum concentration of Domperidone can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Domperidone can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Domperidone can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Domperidone can be decreased when combined with Rosiglitazone.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Domperidone.Approved
SaquinavirThe serum concentration of Domperidone can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Domperidone can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Domperidone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Domperidone.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Domperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
SildenafilThe serum concentration of Domperidone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Domperidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Domperidone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Domperidone can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Domperidone can be decreased when it is combined with Sirolimus.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Domperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Domperidone.Approved
SpironolactoneThe serum concentration of Domperidone can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Domperidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Domperidone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Domperidone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Domperidone can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Domperidone.Approved
SulfinpyrazoneThe serum concentration of Domperidone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Domperidone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Domperidone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TacrineThe serum concentration of Domperidone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Domperidone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Domperidone.Approved
Taurocholic AcidThe serum concentration of Domperidone can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Domperidone can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Domperidone.Approved
TelithromycinThe serum concentration of Domperidone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Domperidone can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Domperidone can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Domperidone can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Domperidone can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Domperidone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Domperidone.Approved
TerfenadineThe serum concentration of Domperidone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Domperidone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Domperidone can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineDomperidone may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Domperidone can be decreased when combined with Theophylline.Approved
ThioridazineThioridazine may increase the QTc-prolonging activities of Domperidone.Approved
ThiotepaThe metabolism of Domperidone can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Domperidone.Approved
TicagrelorThe serum concentration of Domperidone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Domperidone can be increased when it is combined with Ticlopidine.Approved
TipranavirThe metabolism of Domperidone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Domperidone.Approved
TocilizumabThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Domperidone.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TolvaptanThe serum concentration of Domperidone can be increased when it is combined with Tolvaptan.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TrifluoperazineThe serum concentration of Domperidone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Domperidone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Domperidone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
TroleandomycinThe serum concentration of Domperidone can be increased when it is combined with Troleandomycin.Approved
VandetanibDomperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Domperidone.Approved
VemurafenibThe serum concentration of Domperidone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Domperidone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Domperidone can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Domperidone.Approved
VinblastineThe serum concentration of Domperidone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Domperidone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Domperidone can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Domperidone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
ZimelidineThe serum concentration of Domperidone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Domperidone can be increased when it is combined with Ziprasidone.Approved
ZuclopenthixolDomperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take 15 to 30 minutes before meals.
References
Synthesis Reference

Vanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).

General References
  1. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. [PubMed:9663360 ]
External Links
ATC CodesA03FA03
AHFS Codes
  • 56:32.00
  • 56:92.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.8686
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7029
P-glycoprotein inhibitor IInhibitor0.7244
P-glycoprotein inhibitor IIInhibitor0.628
Renal organic cation transporterInhibitor0.6546
CYP450 2C9 substrateNon-substrate0.7974
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6392
CYP450 1A2 substrateInhibitor0.8737
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5577
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8695
Ames testNon AMES toxic0.6608
CarcinogenicityNon-carcinogens0.922
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9828 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7527
hERG inhibition (predictor II)Inhibitor0.917
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
  • Professional Co.
Dosage forms
FormRouteStrength
TabletOral10 mg
Prices
Unit descriptionCostUnit
Domperidone bp powder55.2USD g
Ratio-Domperidone Maleate 10 mg Tablet0.16USD tablet
Apo-Domperidone 10 mg Tablet0.16USD tablet
Mylan-Domperidone 10 mg Tablet0.16USD tablet
Novo-Domperidone 10 mg Tablet0.16USD tablet
Nu-Domperidone 10 mg Tablet0.16USD tablet
Pms-Domperidone 10 mg Tablet0.15USD tablet
Ran-Domperidone 10 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point242.5 °CVanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).
water solubility0.986 mg/LNot Available
logP3.90EL TAYER,N ET AL. (1985)
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0925 mg/mLALOGPS
logP3.7ALOGPS
logP2.9ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability45.61 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Chlorobenzene
  • 4-aminopiperidine
  • Benzenoid
  • Piperidine
  • N-substituted imidazole
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081 ]
  3. de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [PubMed:1683559 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Ali I, Gupta VK, Singh P, Pant HV: Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. doi: 10.1016/j.talanta.2005.06.027. Epub 2005 Jul 22. [PubMed:18970411 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chang SY, Fancher RM, Zhang H, Gan J: Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica. 2010 Feb;40(2):138-45. doi: 10.3109/00498250903406762. [PubMed:20082577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J: Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23. [PubMed:15801545 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
  2. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 Jun 1;97(11):2517-24. [PubMed:8647944 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23